Eli Lilly And Co (LLY) Position Raised by Peoples Financial Services CORP.

Peoples Financial Services CORP. increased its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 4.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,825 shares of the company’s stock after purchasing an additional 750 shares during the period. Peoples Financial Services CORP.’s holdings in Eli Lilly And Co were worth $1,806,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. BlackRock Inc. grew its stake in Eli Lilly And Co by 1.3% in the second quarter. BlackRock Inc. now owns 66,644,897 shares of the company’s stock valued at $5,686,808,000 after acquiring an additional 864,451 shares during the period. Janus Henderson Group PLC grew its stake in Eli Lilly And Co by 7.5% in the second quarter. Janus Henderson Group PLC now owns 10,008,768 shares of the company’s stock valued at $854,049,000 after acquiring an additional 700,582 shares during the period. Morgan Stanley grew its stake in Eli Lilly And Co by 37.8% in the second quarter. Morgan Stanley now owns 4,473,537 shares of the company’s stock valued at $381,727,000 after acquiring an additional 1,227,888 shares during the period. Swiss National Bank grew its stake in Eli Lilly And Co by 2.3% in the second quarter. Swiss National Bank now owns 3,851,143 shares of the company’s stock valued at $328,618,000 after acquiring an additional 84,800 shares during the period. Finally, Fisher Asset Management LLC grew its stake in Eli Lilly And Co by 5.1% in the second quarter. Fisher Asset Management LLC now owns 3,710,066 shares of the company’s stock valued at $316,580,000 after acquiring an additional 180,855 shares during the period. 76.56% of the stock is owned by institutional investors and hedge funds.

In other news, major shareholder Lilly Endowment Inc sold 14,632 shares of the firm’s stock in a transaction that occurred on Monday, October 8th. The stock was sold at an average price of $115.91, for a total value of $1,695,995.12. Following the transaction, the insider now owns 119,191,172 shares in the company, valued at $13,815,448,746.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Eli & Co Lilly sold 10,059 shares of the firm’s stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $14.83, for a total value of $149,174.97. Following the completion of the transaction, the insider now owns 3,894,318 shares in the company, valued at approximately $57,752,735.94. The disclosure for this sale can be found here. Insiders sold 1,785,575 shares of company stock worth $180,166,130 in the last 90 days. Corporate insiders own 0.11% of the company’s stock.

LLY stock opened at $110.48 on Friday. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $116.61. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40. The company has a market capitalization of $115.25 billion, a PE ratio of 25.81, a P/E/G ratio of 1.88 and a beta of 0.29.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The company had revenue of $6.36 billion for the quarter, compared to analyst estimates of $6.05 billion. During the same quarter last year, the company earned $1.11 earnings per share. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. Equities research analysts anticipate that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.

LLY has been the subject of a number of research reports. Goldman Sachs Group set a $100.00 price objective on Eli Lilly And Co and gave the company a “neutral” rating in a research note on Wednesday, July 25th. Credit Suisse Group raised their price objective on Eli Lilly And Co from $84.00 to $86.00 and gave the company an “underperform” rating in a research note on Wednesday, July 25th. BMO Capital Markets raised Eli Lilly And Co from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $107.00 to $130.00 in a research note on Thursday, October 4th. Berenberg Bank cut Eli Lilly And Co from a “buy” rating to a “hold” rating and set a $99.00 price objective for the company. in a research note on Wednesday, July 25th. They noted that the move was a valuation call. Finally, Barclays raised their price objective on Eli Lilly And Co from $98.00 to $107.00 and gave the company an “overweight” rating in a research note on Friday, September 7th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $107.88.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Moving Average (MA)

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply